
Paper

Metal-Free Synthesis of Biaryl- and Teraryl-Cored Diarylmethanes by Ring Transformation of 2*H*-Pyran-2-ones

Α

Fateh V. Singh^{*} Priyanka B. Kole

Chemistry Division, School of Advanced Science, VIT University, Chennai Campus, Chennai 600127, Tamil Nadu, India fatehveer.singh@vit.ac.in



Ar = C₆H₅, 4-BrC₆H₄, 4-ClC₆H₄, 4-MeC₆H₄, 4-OMeC₆H₄, 2-naphthyl, 2-thienyl; R = H, Me

Received: 06.09.2018 Accepted after revision: 26.10.2018 Published online: 30.11.2018 DOI: 10.1055/s-0037-1610332; Art ID: ss-2018-z0598-op

Abstract An efficient metal-free approach for the synthesis of functionalized biaryl-cored diarylmethanes is described by the ring transformation of 2*H*-pyran-2-ones using 4-phenylbutan-2-one as carbanion source. Moreover, 2*H*-pyran-2-ones were reacted with 1,3-diphenylacetone in the presence of base to achieve functionalized teraryl-cored diarylmethanes. All the ring transformation reactions were performed under mild reaction conditions to afford the biaryl- and teraryl-cored reaction products in high yields.

Key words biaryl-cored diarylmethanes, teraryl-cored diarylmethanes, 2*H*-pyran-2-ones, carbanion, ring transformation reactions, 4-phenylbutan-2-one, 1,3-diphenylacetone

Functionalized diarylmethanes are important scaffolds found in various biologically active synthetic and naturally occurring compounds.¹ Diarylmethane-cored compounds are known to exhibit various biological activities such as antibreast cancer,² thyroid hormone and histamine H1-receptor antagonist,^{3,4} antiviral,⁵ antiallergic,⁶ and antidiabetic activities.7 Molecules embedded with diarylmethane units are widely found in various biologically active compounds (Figure 1). Beclobrate (1) has been introduced as potent cholesterol and triglyceride-lowering drug.8 Trimethoprim (2) has been developed as effective antibiotic and used for the treatment of urinary tract infections.⁹ In addition, naturally occurring compound avrainvilleol (3) is isolated from red algae and found to exhibit antioxidant activity.¹⁰ Moreover, the alkaloid papaverine (**4**), isolated from Papaver somniferum L., exhibits diverse biological activities such as antiplasmodic activity,¹¹ cerebral vasodilator,¹² and non-selective phosphodiesterase inhibitory activity.¹³ In addition, various tetronic acid derived chiral analogues of diarylmethanes have been found to show anti-HIV and anticancer activities.¹⁴ Recently diarylmethane derivatives have been used as an important precursors in several dye preparations.¹⁵




Figure 1 Structures of synthetic and natural products of biological importance with diarylmethane units

There are several methods available in literature for the synthesis of diarylmethanes, but most of them are associated with transition-metal-catalyzed coupling reactions such as Pd-catalyzed Suzuki type cross-coupling reactions of benzylic halides with arylboranes.¹⁶ In 2015, Yoshikai and co-workers reported the synthesis of diarylmethanes by *ortho*-CH benzylation of arylimines using Cobalt-Pyphos catalytic system.¹⁷ In 2016, Zhang and co-workers described a one-pot synthesis of diarylmethanes from benzyl chlorides by a Ni-catalyzed reductive cross-coupling reactions.¹⁸

Furthermore, synthesis of allyldiarylmethanes was accomplished via 1,6-conjugate allylation of p-quinonemethides using $B(C_6F_5)_3$ as catalyst.¹⁹ In 2016, Hemelaere and co-workers developed the synthesis of diarylmethanes by Friedel–Crafts reaction of benzyl fluorides in the presence of TFA.²⁰ Furthermore, the synthesis of diarylВ

methanes was achieved through transition-metal-free cross-coupling reaction of benzylic bromides with arylbo-ronic acids in the presence of Cs_2CO_3 using the solvent combination BTF/H₂O (10:1).²¹

Most of the existing approaches are associated with some limitations such as the use of toxic transition-metal catalysts and harsh reaction conditions. Despite the availability of several existing approaches, there is still scope to develop a new approach that could overcome the problems associated with them and offers the flexibility of introducing a wide range of functional groups in the diarylmethane architecture.

Herein, we report a metal-free approach for the synthesis of functionalized biaryl-cored diarylmethanes **9** in high yields by the ring transformation of 6-aryl-2*H*-pyran-2-ones **8** using 4-phenylbutan-2-one (**6**) as a source of nucle-ophile. The parent precursors **5** were synthesized by the reaction of methyl 2-cyano-3,3-dimethylsulfanylacrylate with functionalized acetophenones in DMSO at room temperature under alkaline conditions.²² Furthermore, the substrates **5** were reacted with secondary amines in methanol at reflux temperature to synthesize 6-aryl-4-amino-2*H*-pyran-2-ones **8**.²²


The ring transformation of 2*H*-pyran-2-ones has been used to synthesize various arenes,²³ heteroarenes,²⁴ and fused cyclic systems.²⁵ Recently, we have reported the ultrasound-assisted synthesis of functionalized 2-tetralones via ring transformation of 2*H*-pyran-2-ones.²⁶

Our approach to prepare functionalized biaryl-cored diarylmethanes **9** was based on the ring transformation of 6aryl-2*H*-pyran-2-ones **5** and **8** using 4-phenylbutan-2-one (**6**) as a carbanion source. Both substrates **5** and **8** have three electrophilic centers at C-2, C-4, and C-6. The presence of the electron-withdrawing substituent at C-3 position of pyran ring and the extended conjugation makes the latter position to be more reactive towards nucleophiles.


Initially, our studies were focused on the ring transformation of 3-cyano-4-methylsulfanyl-2*H*-pyran-2-ones (**5a**) with 4-phenylbutan-2-one (**6**). The ring transformation of substrate **5a** with **6** was performed in DMF in the presence of KOH at room temperature (Table 1, entry 1). Unfortunately, the reaction suffered from several unwanted side reactions and ring transformed product **7a** was obtained in 50% yield. When other substrates **5b** and **5c** were used in similar reactions and the desired products were observed in slightly improved yields (entries 2 and 3). Probably, the presence of SMe group at C-4 position of lactone ring in substrate **5** makes this position more susceptible for nucleophilic attack, which leads to various undesired side products.

Next, our efforts were directed to limit the reactivity of 2*H*-pyran-2-ones **5** at C-4 position towards the nucleophile. In order to limit the reactivity at C-4 position, the leaving group SMe in substrates **5** was replaced with *tert*-amino functionality by treating with cyclic amines and new sub-

 Table 1
 Ring Transformation of 6-Aryl-4-(methylthio)-2-oxo-2Hpyran-3-carbonitriles
 5a-c
 with 4-Phenylbutan-2-one (6)
 6




strates 6-phenyl-4-amino-2*H*-pyran-2-ones **8** were synthesized.²² Further, to know the influence of amino functionality in the ring transformation reaction, the substrate 2-oxo-6-phenyl-4-(piperidin-1-yl)-2*H*-pyran-3-carbonitrile (**8a**) was treated with the same ketone **6** under similar reaction conditions and a significant improvement was observed in the yield of ring-transformed product **9a** (Scheme 1).




After that our efforts were directed towards the screening of different solvents using 8a as model substrate. Various polar and nonpolar solvents were employed for the ring transformation of model substrate **8a** to the corresponding synthesis of diarylmethane derivative **9a** using ketone **6** as source of carbanion and the results obtained are summarized in Table 2. Initially, the ring transformation reaction of 8a was performed in polar and aprotic solvents DMF and DMSO, and the reaction product 9a was isolated in 85% and 82% yield, respectively (Table 2, entries 1 and 2). The yield of ring transformed product was slightly lowered when acetonitrile was used as solvent (entry 3). The yield was further reduced up to 69% yield in EtOAc (entry 4). Additionally, the ring transformation reaction was performed in polar and protic solvents but could not proceed (entries 5-7). The ring transformation reaction could proceed in dichloromethane but desired product 9a was obtained in moderate yield (entry 8). The course of reaction was investigated in aprotic and nonpolar solvents such as benzene and toluene. The ring transformed product was formed in toluene but was observed only in traces in benzene (entries 9 and 10).

Syn thesis

Finally, the reaction was performed in THF, diethyl ether, and 1,4-dioxane but the reaction did not proceed in any of these solvents (entries 11–13).







Entry	Solvent	Reaction time (h)	9a Yield (%)
1	DMF	10	85
2	DMSO	10	82
3	MeCN	10	79
4	EtOAc	10	69
5	AcOH	14	-
6	MeOH	14	-
7	EtOH	14	-
8	CH ₂ Cl ₂	12	58
9	toluene	12	30
10	benzene	12	-
11	Et ₂ O	12	-
12	THF	14	-
13	1,4-dioxane	14	-

After determining the optimal solvent, our aim was to screen the different bases for the same ring transformation reaction. Several bases were employed for the ring transformation of **8a** to the desired product **9a** and results are listed in Table 3. Initially, the reaction was carried out with KOH in DMF and ring transformation product was obtained in 85% yield (Table 3, entry 1). Similarly, the reaction was tested with NaHCO₃ under the same reaction condition and the product **9a** was isolated in 75% yield (entry 2). Additionally, K_2CO_3 and Cs_2CO_3 were also used as base for same reaction and desired product **9a** was achieved in 65% and 60% yield, respectively (entries 3 and 4). The course of reaction was quite similar with LiOH and the reaction product **9a** was isolated in 63% yield (entry 5).

After the optimization studies, the presence of KOH as base and DMF as solvent at room temperature for 10 hours was found as the best reaction conditions for the ring transformation of 6-phenyl-2*H*-pyran-2-one **8a** to 2-benzyl-3-methyl-5-(piperidin-1-yl)[1,1'-biphenyl]-4-carbonitrile (**9a**).


After achieving the best reaction conditions, a series of biaryl-cored diarylmethanes **9a–k** were synthesized in 78–94% yields by the reaction of various 2*H*-pyran-2-ones **8a–k**





with 4-phenyl-butan-2-one (**6**) in DMF in the presence of KOH for 10–14 hours at room temperature (Table 4, entries 1–11). The ring transformation reaction proceeded well with both electron-withdrawing and electron-donating groups on the aromatic ring of 6-aryl-2*H*-pyran-2-ones **8**. Notably, the ring transformation products **9f-h** were ob-

 Table 4
 Synthesis of Biaryl-Cored Diarylmethanes
 9a-k
 via Ring Transformation of 6-Aryl-2H-pyran-2-ones
 8a-k





1	Ph	Н	piperidin-1-yl	10	85
2	Ph	Н	4-phenylpiperazin-1-yl	10	82
3	$4-CIC_6H_4$	Н	piperidin-1-yl	14	78
4	$4-BrC_6H_4$	Н	piperidin-1-yl	12	82
5	$4-BrC_6H_4$	Н	4-phenylpiperazin-1-yl	12	80
6	$4-MeC_6H_4$	Н	piperidin-1-yl	10	94
7	4-MeOC ₆ H ₄	Н	piperidin-1-yl	10	90
8	4-MeOC ₆ H ₄	Н	4-phenylpiperazin-1-yl	10	92
9	2-naphthyl	Н	piperidin-1-yl	10	88
10	Ph	Me	4-phenylpiperazin-1-yl	12	78
11	2-thienyl	Н	piperidin-1-yl	10	83

С

Syn thesis

F. V. Singh, P. B. Kole

D




 Table 5
 Synthesis of Teraryl-Cored Diarylmethanes


 11
 via

tained in slightly higher yields when the reactions were performed with the substrates **8f-h** (entries 6–8) having electron-donating groups compared to substrates with electron-withdrawing groups **8c-e** (entries 3–5). Furthermore, the ring transformation reaction proceeded well with substrate **8i** having naphthyl group at C-6 position and the desired product **9i** was isolated in 88% yield (entry 9). Additionally, the course of reaction was also investigated with the substrate **8j** having methyl group at C-5 position and reaction proceeded well with up to 78% yield (entry 10). The course of reaction was also evaluated with the substrate **8k** containing thiophene functionality at C-6 position and reaction worked well with up to 83% yield (entry 11).

In order to generalize this approach, the same synthetic protocol was applied to construct teraryl-cored diarylmethanes **11**. To achieve the synthesis of teraryl-cored diarylmethanes **11**, the similar substrates 6-aryl-2*H*-pyran-2ones **8** were treated with 1,3-diphenylacetone (**10**) in DMF in the presence of KOH at room temperature and terarylcored diarylmethanes **11** were obtained 74–95% yields (Table 5, entries 1–11). Various functional groups were successfully tolerated during these ring transformations.

It was observed that the course of reaction was quite similar with both electron-donating and -withdrawing cored substrates but ring transformation products were obtained in slightly higher yields in the case of substrates hav-





ing electron-donating functionalities (Table 5, entries 6–8). Additionally, the reaction was found to be slightly slower when substrates **8j** and **8l** having methyl group at C-5 position were used and reaction products were obtained in 74% and 79% yield, respectively (entries 10 and 11). All the synthesized compounds were characterized by spectroscopic analysis.


Finally, the reaction of substrate **5a** was performed with 1,3-diphenylacetone (**10**) under similar reaction conditions. Expectedly, the reaction suffered from some undesired side reactions probably due to the presence of good leaving SMe at C-4 position in substrate **5a**, which makes this position more vulnerable towards the nucleophile. The ring transformation product **12a** was isolated in 62% yield (Scheme 2). Unfortunately, we could not isolate any side product from the reaction mixture. The isolated compound **12a** was characterized as 3'-benzyl-5'-(methylthio)-[1,1':2',1"-terphenyl]-4'-carbonitrile by its spectroscopic analysis.

The possible mechanism for the ring transformation of 2*H*-pyran-2-ones **8** with 4-phenylbutan-2-one (**6**) to diarylmethanes **9** is described in Scheme 3.²⁷ Initially, the formation of bicyclic intermediate **13** takes place by the nucleophilic attack of anion generated from ketone **6** to the C-6 position of 2*H*-pyran-2-ones **8**, followed by intramolecular cyclization involving the carbonyl functionality of **6** and C-3 of the pyranone ring. Furthermore, the bicyclic intermediate **13** transforms to final product **9** on decarboxylation followed by dehydration.

In conclusion, we have developed a facile metal-free synthetic methodology for the synthesis of functionalized biaryl-cored diarylmethanes **9** through carbanion-induced ring transformation of 6-aryl-2*H*-pyran-2-ones **8** in good yields. In addition, the same approach was employed to achieve the synthesis of teraryl-cored diarylmethanes **11**. Our methodology for the synthesis of functionalized diarylmethanes is simple, economical and does not require any toxic transition metal. Further investigations about this ring transformation approach are currently in progress.

Melting points were measured with REMI DDMS 2545 melting point apparatus. IR spectra were recorded with a Thermo Scientific Nicolet Nexus 470FT-IR spectrophotometer and band positions are reported in reciprocal centimeters. Samples were subjected to ATR mode to record the IR data. ¹H NMR and ¹³C NMR spectra were recorded on a Bruker AV-400 spectrometer using the solvents indicated at 400 and F. V. Singh, P. B. Kole

Paper



Ε

100 MHz, respectively. Mass spectra (m/z) were recorded under the conditions of electron ionization (El). All reactions were monitored by TLC that was performed on pre-coated sheets of silica gel 60 and column chromatography was performed with Al₂O₃ (neutral, 95%) (Avra synthesis Pvt. Ltd.). Hexane and EtOAc were used as eluting solvents and bought from Avra Synthesis Pvt. Ltd. DMF was bought from Avra Synthesis Pvt. Ltd and was used without further purification.

Diarylmethanes 7a-c; General Procedure

A mixture of 3-cyano-4-methylsulfanyl-2H-pyran-2-one **5** (1.0 mmol, 1.0 equiv), 4-phenylbutan-2-one (**6**; 0.18 mL, 1.2 mmol, 1.2 equiv), and powdered KOH (84 mg, 1.5 mmol, 1.5 equiv) in DMF (5 mL) was stirred at r.t. for 10–12 h. The course of reaction was monitored by TLC. On completion of the reaction, few ice pieces were added to the reaction mixture and neutralized with aq 2 M HCl. The mixture was extracted with EtOAc (3×10 mL), the combined organic layers were dried (anhyd Na₂SO₄), filtered, and concentrated under vacuum. The crude residue was purified by neutral alumina column chromatography using EtOAc–hexane (1:49) as an eluent and isolated products were characterized as diarylmethanes **7** by their spectroscopic analysis (Table 1).

2-Benzyl-3-methyl-5-(methylthio)[1,1'-biphenyl]-4-carbonitrile (7a)

White solid; yield: 164 mg (0.5 mmol, 50%); mp 148–150 °C; R_f = 0.5 (EtOAc–hexane 1:49).

IR (ATR): 2212 cm⁻¹ (C≡N).

¹H NMR (400 MHz, CDCl₃): δ = 2.33 (s, 3 H, CH₃), 2.46 (s, 3 H, SCH₃), 3.88 (s, 2 H, CH₂), 6.81 (d, *J* = 7.2 Hz, 2 H, ArH), 6.98 (s, 1 H, ArH), 7.05–7.20 (m, 5 H, ArH), 7.22–7.28 (m, 3 H, ArH).

¹³C NMR (100 MHz, CDCl₃): δ = 15.9, 18.9, 35.8, 112.1, 116.6, 125.4, 126.1, 127.7, 127.9, 128.3, 128.5, 128.6, 133.8, 139.6, 140.6, 141.2, 143.3, 147.8.

GC-MS: $m/z = 330 [M + 1]^+$.

Anal. Calcd for $C_{22}H_{19}$ NS: C, 80.20; H, 5.81; N, 4.25; S, 9.73. Found: C, 79.75; H, 5.83; N, 4.20; S, 9.06.

2-Benzyl-4'-bromo-3-methyl-5-(methylthio)[1,1'-biphenyl]-4carbonitrile (7b)

White solid; yield: 212 mg (0.52 mmol, 52%); mp 150–152 °C; R_f = 0.5 (EtOAc–hexane 1:49).

IR (ATR): 2214 cm⁻¹ (C≡N).

¹H NMR (400 MHz, CDCl₃): δ = 2.34 (s, 3 H, CH₃), 2.46 (s, 3 H, SCH₃), 3.86 (s, 2 H, CH₂), 6.79 (d, J = 6.8 Hz, 2 H, ArH), 6.94 (s, 1 H, ArH), 6.97 (td, J₁ = 8.8 Hz, J₂ = 2.0 Hz, 2 H, ArH), 7.07–7.20 (m, 3 H, ArH), 7.38 (td, J₁ = 8.8 Hz, J₂ = 2.0 Hz, 2 H, ArH).

 ^{13}C NMR (100 MHz, CDCl₃): δ = 15.8, 18.9, 35.7, 112.4, 116.5, 122.2, 125.1, 126.3, 127.6, 128.7, 130.2, 131.5, 133.6, 139.3, 139.4, 141.5, 143.4, 146.5.

GC-MS: $m/z = 409 [M + 1]^+, 410 [M + 2]^+.$

Anal. Calcd for $C_{22}H_{18}BrNS:$ C, 64.71; H, 4.44; N, 3.43; S, 7.85. Found: C, 64.69; H, 4.50; N, 3.39; S, 7.81.

2-Benzyl-4'-methoxy-3-methyl-5-(methylthio)[1,1'-biphenyl]-4carbonitrile (7c)

White solid; yield: 204 mg (0.57 mmol, 57%); mp 144–146 °C; R_f = 0.5 (EtOAc–hexane 1:49).

IR (ATR): 2214 cm⁻¹ (C≡N).

¹H NMR (400 MHz, CDCl₃): δ = 2.32 (s, 3 H, CH₃), 2.46 (s, 3 H, SCH₃), 3.73 (s, 3 H, OCH₃), 3.90 (s, 2 H, CH₂), 6.78 (td, J_1 = 8.8 Hz, J_2 = 2.0 Hz, 2 H, ArH), 6.82 (d, J = 7.2 Hz, 2 H, ArH), 6.98 (s, 1 H, ArH), 7.03 (td, J_1 = 8.8 Hz, J_2 = 2.0 Hz, 2 H, ArH), 7.08–7.20 (m, 3 H, ArH).

 ^{13}C NMR (100 MHz, CDCl_3): δ = 15.9, 18.9, 35.8, 55.3, 111.8, 113.7, 116.7, 125.6, 126.1, 127.7, 128.6, 129.7, 132.9, 133.9, 139.7, 141.1, 143.3, 147.5, 159.3.

GC-MS: $m/z = 360 [M + 1]^+$.

Anal. Calcd for $C_{23}H_{21}$ NOS: C, 76.85; H, 5.89; N, 3.90; S, 8.92. Found: C, 76.10; H, 5.84; N, 3.84; S, 8.58.

Syn thesis

F. V. Singh, P. B. Kole

Biaryl-Cored Diarylmethanes 9a-k; General Procedure

A mixture of 2*H*-pyran-2-one **8** (1.0 mmol, 1.0 equiv), 4-phenylbutan-2-one (**6**; 0.18 mL, 1.2 mmol, 1.2 equiv), and powdered KOH (84 mg, 1.5 mmol, 1.5 equiv) in DMF (5 mL) was stirred at r.t. for 10–14 h. The course of reaction was monitored by TLC. On completion of the reaction, few ice pieces were added to the reaction mixture and neutralized with aq 2 M HCl. The reaction mixture was extracted with EtOAc (3 × 10 mL), the combined organic layers were dried (anhyd Na₂SO₄), filtered, and concentrated under vacuum. The crude residue was purified by neutral alumina column chromatography using EtO-Ac-hexane (1:49) as an eluent and isolated products were characterized as biaryl-cored diarylmethanes **9** by their spectroscopic analysis (Table 4).

2-Benzyl-3-methyl-5-(piperidin-1-yl)[1,1'-biphenyl]-4-carbonitrile (9a)

White solid; yield: 311 mg, 0.85 mmol (85%); mp 114–116 °C; R_f = 0.5 (EtOAc–hexane 1:49).

IR (ATR): 2215 cm⁻¹ (C≡N).

¹H NMR (400 MHz, CDCl₃): δ = 1.46–1.54 (m, 2 H, CH₂), 1.66–1.75 (m, 4 H, 2 × CH₂), 2.30 (s, 3 H, CH₃), 3.06 (t, *J* = 5.2 Hz, 4 H, 2 × NCH₂), 3.84 (s, 2 H, CH₂), 6.70 (s, 1 H, ArH), 6.82 (d, *J* = 7.6 Hz, 2 H, ArH), 7.03–7.18 (m, 5 H, ArH), 7.20–7.25 (m, 3 H, ArH).

 ^{13}C NMR (100 MHz, CDCl₃): δ = 18.9, 24.1, 26.3, 35.7, 53.6, 107.5, 118.1, 118.4, 125.9, 127.5, 127.8, 128.2, 128.5, 128.6, 129.6, 140.3, 141.4, 143.4, 148.1, 155.6.

GC-MS: $m/z = 367 [M + 1]^+$.

Anal. Calcd for $C_{26}H_{26}N_2$: C, 85.21; H, 7.15; N, 7.64. Found: C, 85.04; H, 7.18; N, 7.52.

2-Benzyl-3-methyl-5-(4-phenylpiperazin-1-yl)[1,1'-biphenyl]-4carbonitrile (9b)

White solid; yield: 363 mg (0.82 mmol, 82%); mp 180–182 °C; R_f = 0.5 (EtOAc–hexane 1:49).

IR (ATR): 2210 cm⁻¹ (C≡N).

¹H NMR (400 MHz, CDCl₃): δ = 2.32 (s, 3 H, CH₃), 3.25–3.35 (m, 8 H, 4 × NCH₂), 3.86 (s, 2 H, CH₂), 6.76 (s, 1 H, ArH), 6.81 (t, *J* = 7.6 Hz, 3 H, ArH), 6.89 (d, *J* = 8.4 Hz, 2 H, ArH), 7.03–7.20 (m, 7 H, ArH), 7.21–7.26 (m, 3 H, ArH).

 ^{13}C NMR (100 MHz, CDCl₃): δ = 19.0, 24.2, 35.7, 49.6, 51.9, 107.6, 116.4, 117.9, 118.3, 120.1, 126.0, 127.7, 127.8, 128.3, 128.5, 128.6, 129.2, 130.6, 140.1, 141.2, 143.8, 148.4, 151.2, 154.1.

GC-MS: $m/z = 444 [M + 1]^+$.

Anal. Calcd for C₃₁H₂₉N₃: C, 83.94; H, 6.59; N, 9.47. Found: C, 83.55; H, 6.58; N, 9.37.

2-Benzyl-4'-chloro-3-methyl-5-(piperidin-1-yl)[1,1'-biphenyl]-4carbonitrile (9c)

White solid; yield: 312 mg (0.77 mmol, 78%); mp 141–143 °C; R_f = 0.5 (EtOAc–hexane 1:49).

IR (ATR): 2218 cm⁻¹ (C≡N).

¹H NMR (400 MHz, CDCl₃): δ = 1.46–1.57 (m, 2 H, CH₂), 1.66–1.75 (m, 4 H, 2 × CH₂), 2.30 (s, 3 H, CH₃), 3.06 (t, *J* = 5.6 Hz, 4 H, 2 × NCH₂), 3.81 (s, 2 H, CH₂), 6.65 (s, 1 H, ArH), 6.80 (d, *J* = 7.2 Hz, 2 H, ArH), 7.01 (d, *J* = 8.4 Hz, 2 H, ArH), 7.04–7.21 (m, 5 H, ArH).

 ^{13}C NMR (100 MHz, CDCl₃): δ = 18.9, 24.1, 26.2, 35.6, 53.5, 107.7, 117.9, 118.2, 126.0, 127.7, 128.4, 128.6, 129.4, 129.9, 133.7, 139.8, 140.0, 143.5, 146.9, 155.7.

GC-MS: $m/z = 401 [M + 1]^+, 402 [M + 2]^+.$

Anal. Calcd for $C_{26}H_{25}CIN_2:$ C, 77.89; H, 6.28; N, 6.99. Found: C, 77.39; H, 6.41; N, 6.43.

2-Benzyl-4'-bromo-3-methyl-5-(piperidin-1-yl)[1,1'-biphenyl]-4carbonitrile (9d)

White solid; yield: 364 mg (0.82 mmol, 82%); mp 116–118 °C; R_f = 0.5 (EtOAc–hexane 1:49).

IR (ATR): 2217 cm⁻¹ (C≡N).

¹H NMR (400 MHz, CDCl₃): δ = 1.47–1.56 (m, 2 H, CH₂), 1.66–1.73 (m, 4 H, 2 × CH₂), 2.30 (s, 3 H, CH₃), 3.06 (t, *J* = 4.8 Hz, 4 H, 2 × NCH₂), 3.81 (s, 2 H, CH₂), 6.65 (s, 1 H, ArH), 6.80 (d, *J* = 7.6 Hz, 2 H, ArH), 6.95 (d, *J* = 8.0 Hz, 2 H, ArH), 7.03–7.19 (m, 3 H, ArH), 7.34 (d, *J* = 8.0 Hz, 2 H, ArH).

 ^{13}C NMR (100 MHz, CDCl_3): δ = 18.9, 24.1, 26.2, 35.6, 53.5, 107.7, 117.9, 118.1, 121.9, 126.1, 127.7, 128.6, 129.4, 130.2, 131.3, 140.0, 140.2, 143.6, 146.8, 155.7.

GC-MS: $m/z = 446 [M + 1]^+, 447 [M + 2]^+.$

Anal. Calcd for $C_{26}H_{25}BrN_2$: C, 70.11; H, 5.66; N, 6.29. Found: C, 70.03; H, 5.66; N, 6.11.

2-Benzyl-4'-bromo-3-methyl-5-(4-phenylpiperazin-1-yl)[1,1'-bi-phenyl]-4-carbonitrile (9e)

White solid; yield: 417 mg (0.79 mmol, 80%); mp 172–174 °C; R_f = 0.5 (EtOAc–hexane 1:49).

IR (ATR): 2210 cm⁻¹ (C≡N).

¹H NMR (400 MHz, CDCl₃): δ = 2.34 (s, 3 H, CH₃), 3.25–3.36 (m, 8 H, 4 × NCH₂), 3.84 (s, 2 H, CH₂), 6.71 (s, 1 H, ArH), 6.79–6.85 (m, 3 H, ArH), 6.91 (d, J = 8.0 Hz, 2 H, ArH), 6.97 (td, J₁ = 8.4 Hz, J₂ = 1.6 Hz, 2 H, ArH), 7.06–7.25 (m, 5 H, ArH), 7.37 (td, J₁ = 8.4 Hz, J₂ = 1.6 Hz, 2 H, ArH).

 ^{13}C NMR (100 MHz, CDCl_3): δ = 18.9, 35.6, 49.6, 51.9, 107.8, 116.4, 117.7, 118.1, 120.1, 122.0, 126.1, 127.7, 128.6, 129.2, 130.2, 130.4, 131.4, 139.8, 140.0, 143.9, 147.1, 151.2, 154.2.

GC-MS: $m/z = 523 [M + 1]^+$, $524 [M + 2]^+$.

Anal. Calcd for $C_{31}H_{28}BrN_3$: C, 71.26; H, 5.40; N, 8.04. Found: C, 71.19; H, 5.47; N, 7.91.

2-Benzyl-3,4'-dimethyl-5-(piperidin-1-yl)[1,1'-biphenyl]-4-carbonitrile (9f)

White solid; yield: 357 mg (0.94 mmol, 94%); mp 162–164 °C; R_f = 0.5 (EtOAc–hexane 1:49).

IR (ATR): 2215 cm⁻¹ (C≡N).

¹H NMR (400 MHz, CDCl₃): δ = 1.45–1.56 (m, 2 H, CH₂), 1.64–1.75 (m, 4 H, 2 × CH₂), 2.26 (s, 3 H, CH₃), 2.28 (s, 3 H, CH₃), 3.05 (t, *J* = 5.2 Hz, 4 H, 2 × NCH₂), 3.85 (s, 2 H, CH₂), 6.70 (s, 1 H, ArH), 6.83 (d, *J* = 7.6 Hz, 2 H, ArH), 6.95–7.10 (m, 5 H, ArH), 7.14 (t, *J* = 7.6 Hz, 2 H, ArH).

 ^{13}C NMR (100 MHz, CDCl_3): δ = 18.9, 21.2, 24.2, 26.3, 35.7, 53.6, 107.3, 118.1, 118.4, 125.9, 127.8, 128.5, 128.9, 129.7, 137.3, 138.5, 140.4, 143.4, 148.1, 148.2, 155.6.

GC-MS: $m/z = 381 [M + 1]^+$.

Anal. Calcd for $C_{27}H_{28}N_2$: C, 85.22; H, 7.42; N, 7.36. Found: C, 84.71; H, 7.42; N, 7.16.

Paper

2-Benzyl-4'-methoxy-3-methyl-5-(piperidin-1-yl)[1,1'-biphenyl]-4-carbonitrile (9g)

White solid; yield: 356 mg (0.90 mmol, 90%); mp 172–174 °C; R_f = 0.5 (EtOAc–hexane 1:49).

IR (ATR): 2213 cm⁻¹ (C≡N).

¹H NMR (400 MHz, CDCl₃): δ = 1.45–1.58 (m, 2 H, CH₂), 1.66–1.75 (m, 4 H, 2 × CH₂), 2.28 (s, 3 H, CH₃), 3.05 (t, *J* = 5.2 Hz, 4 H, 2 × NCH₂), 3.71 (s, 3 H, OCH₃), 3.86 (s, 2 H, CH₂), 6.70 (s, 1 H, ArH), 6.75 (d, *J* = 8.0 Hz, 2 H, ArH), 6.83 (d, *J* = 7.2 Hz, 2 H, ArH), 7.02 (d, *J* = 8.0 Hz, 2 H, ArH), 7.04–7.10 (m, 1 H, ArH), 7.14 (t, *J* = 7.2 Hz, 2 H, ArH).

 ^{13}C NMR (100 MHz, CDCl₃): δ = 18.9, 24.2, 26.3, 35.7, 53.6, 55.3, 107.2, 113.6, 118.2, 118.5, 125.9, 127.8, 128.5, 129.7, 133.8, 140.4, 143.3, 147.9, 155.6, 159.1.

GC-MS: $m/z = 397 [M + 1]^+$.

Anal. Calcd for $C_{27}H_{28}N_2O$: C, 81.78; H, 7.12; N, 7.06. Found: C, 81.11; H, 7.14; N, 6.92.

2-Benzyl-4'-methoxy-3-methyl-5-(4-phenylpiperazin-1-yl)[1,1'biphenyl]-4-carbonitrile (9h)

White solid; yield: 435 mg (0.92 mmol, 92%); mp 174–176 °C; R_f = 0.5 (EtOAc–hexane 1:49).

IR (ATR): 2214 cm⁻¹ (C≡N).

¹H NMR (400 MHz, CDCl₃): δ = 2.31 (s, 3 H, CH₃), 3.25–3.36 (m, 8 H, $4 \times$ NCH₂), 3.72 (s, 3 H, OCH₃), 3.89 (s, 2 H, CH₂), 6.75–6.77 (m, 2 H, ArH), 6.78 (s, 1 H, ArH), 6.81–6.87 (m, 2 H, ArH), 6.88–6.95 (m, 2 H, ArH), 7.04 (d, *J* = 8.8 Hz, 2 H, ArH), 7.06–7.12 (m, 1 H, ArH), 7.13–7.24 (m, 5 H, ArH).

 ^{13}C NMR (100 MHz, CDCl₃): δ = 19.0, 35.7, 49.6, 51.9, 55.3, 107.3, 113.7, 116.4, 118.5, 120.1, 126.0, 127.8, 128.5, 128.7, 129.2, 129.7, 130.8, 133.5, 140.2, 143.7, 148.1, 151.2, 154.1, 159.2.

GC-MS: $m/z = 474 [M + 1]^+$.

Anal. Calcd for $C_{32}H_{31}N_3O$: C, 81.15; H, 6.60; N, 8.87. Found: C, 81.02; H, 7.12; N, 8.71.

3-Benzyl-2-methyl-4-(naphthalen-2-yl)-6-(piperidin-1-yl)benzonitrile (9i)

White solid; yield: 366 mg (0.88 mmol, 88%); mp 162–164 °C; R_f = 0.5 (EtOAc–hexane 1:49).

IR (ATR): 2213 cm⁻¹ (C≡N).

¹H NMR (400 MHz, CDCl₃): δ = 1.44–1.55 (m, 2 H, CH₂), 1.66–1.76 (m, 4 H, 2 × CH₂), 2.33 (s, 3 H, CH₃), 3.07 (t, *J* = 5.2 Hz, 4 H, 2 × NCH₂), 3.87 (s, 2 H, CH₂), 6.79 (s, 1 H, ArH), 6.82 (d, *J* = 6.8 Hz, 2 H, ArH), 7.07 (d, *J* = 6.8 Hz, 1 H, ArH), 7.13 (t, *J* = 7.6 Hz, 2 H, ArH), 7.21 (dd, *J*₁ = 8.4 Hz, *J*₂ = 1.6 Hz, 1 H, ArH), 7.35–7.41 (m, 2 H, ArH), 7.54 (s, 1 H, ArH), 7.58–7.65 (m, 1 H, ArH), 7.68 (d, *J* = 8.8 Hz, 1 H, ArH), 7.70–7.78 (m, 1 H, ArH).

 ^{13}C NMR (100 MHz, CDCl₃): δ = 19.0, 24.2, 26.3, 35.8, 53.6, 107.6, 118.1, 118.6, 125.9, 126.3, 126.4, 126.8, 127.5, 127.6, 127.7, 127.8, 128.1, 128.5, 129.8, 132.5, 133.0, 138.9, 140.3, 143.5, 148.1, 155.7.

GC-MS: $m/z = 417 [M + 1]^+$.

Anal. Calcd for $C_{30}H_{28}N_2$: C, 86.50; H, 6.78; N, 6.72. Found: C, 86.17; H, 6.77; N, 6.60.

2-Benzyl-3,6-dimethyl-5-(4-phenylpiperazin-1-yl)[1,1'-biphenyl]-4-carbonitrile (9j)

White solid; yield: 356 mg (0.78 mmol, 78%); mp 140–142 °C; R_f = 0.5 (EtOAc–hexane 1:49).

IR (ATR): 2215 cm⁻¹ (C=N).

¹H NMR (400 MHz, CDCl₃): δ = 1.89 (s, 3 H, CH₃), 2.30 (s, 3 H, CH₃), 3.18–3.55 (m, 8 H, 4 × NCH₂), 3.69 (s, 2 H, CH₂), 6.72 (d, J = 7.2 Hz, 2 H, ArH), 6.79 (t, J = 7.2 Hz, 1 H, ArH), 6.85–6.94 (m, 4 H, ArH), 7.01–7.15 (m, 3 H, ArH), 7.16–7.24 (m, 5 H, ArH).

 $^{13}\text{CNMR}$ (100 MHz, CDCl₃): δ = 16.9, 18.5, 36.6, 50.5, 50.6, 111.7, 116.6, 118.4, 119.9, 125.8, 127.3, 127.8, 128.2, 128.3, 128.5, 129.1, 133.5, 134.3, 139.8, 140.1, 140.2, 148.9, 151.5, 151.8.

GC-MS: $m/z = 458 [M + 1]^+$.

Anal. Calcd for $C_{32}H_{31}N_3$: C, 83.99; H, 6.83; N, 9.18. Found: C, 83.67; H, 6.87; N, 8.99.

3-Benzyl-2-methyl-6-(piperidin-1-yl)-4-(thiophen-2-yl)benzonitrile (9k)

White solid; yield: 308 mg (0.83 mmol (83%); mp 115–117 °C; R_f = 0.5 (EtOAc–hexane 1:49).

IR (ATR): 2215 cm⁻¹ (C≡N).

¹H NMR (400 MHz, CDCl₃): δ = 1.49–1.58 (m, 2 H, CH₂), 1.67–1.76 (m, 4 H, 2 × CH₂), 2.30 (s, 3 H, CH₃), 3.07 (t, *J* = 5.2 Hz, 4 H, 2 × NCH₂), 4.00 (s, 2 H, CH₂), 6.78 (ds, *J* = 3.2 Hz, 1 H, ArH), 6.85–6.91 (m, 4 H, ArH), 7.11 (t, *J* = 7.2 Hz, 1 H, ArH), 7.14–7.25 (m, 3 H, ArH).

 ^{13}C NMR (100 MHz, CDCl₃): δ = 19.0, 24.1, 26.2, 35.9, 53.5, 107.9, 117.9, 119.2, 126.0, 126.1, 126.9, 127.3, 127.8, 128.6, 130.2, 140.2, 140.4, 142.1, 143.7, 155.5.

GC-MS: $m/z = 373 [M + 1]^+$.

Anal. Calcd for $C_{24}H_{24}N_2S$: C, 77.38; H, 6.49; N, 7.52; S, 8.61. Found: C, 77.68; H, 6.44; N, 7.43; S, 8.50.

Teraryl-Cored Diarylmethanes 11a-j and 11l; General Procedure

A mixture of 2*H*-pyran-2-one **8** (1.0 mmol, 1.0 equiv), 1,3-diphenylacetone (**10**; 0.24 mL, 1.2 mmol, 1.2 equiv), and powdered KOH (84 mg, 1.5 mmol, 1.5 equiv) in DMF (5 mL) was stirred at r.t. for 10–15 h. The progress of the reaction was checked by TLC. On completion of the reaction, few ice pieces were added to the reaction mixture and neutralized with aq 2 M HCl. The reaction mixture was extracted with EtOAc (3 × 10 mL), the combined organic layers were dried (anhyd Na₂SO₄), filtered, and evaporated under vacuum. The crude residue was purified by neutral alumina column chromatography using EtO-Ac-hexane (1:49) as an eluent and compounds were characterized as teraryl-cored diarylmethanes **11** by their spectroscopic analysis (Table 5).

3'-Benzyl-5'-(piperidin-1-yl)[1,1':2',1"-terphenyl]-4'-carbonitrile (11a)

White solid; yield: 376 mg (0.88 mmol, 88%); mp 145–148 °C; R_f = 0.5 (EtOAc–hexane 1:49).

IR (ATR): 2214 cm⁻¹ (C≡N).

¹H NMR (400 MHz, CDCl₃): δ = 1.49–1.58 (m, 2 H, CH₂), 1.69–1.78 (m, 4 H, 2 × CH₂), 3.13 (t, *J* = 5.2 Hz, 4 H, 2 × NCH₂), 4.06 (s, 2 H, CH₂), 6.71–6.81 (m, 3 H, ArH), 6.86 (s, 1 H, ArH), 6.90–6.95 (m, 2 H, ArH), 6.96–7.10 (m, 9 H, ArH), 7.17–7.26 (m, 1 H, ArH).

 ^{13}C NMR (100 MHz, CDCl₃): δ = 24.1, 26.2, 38.4, 53.6, 107.2, 118.9, 125.9, 126.8, 126.9, 127.6, 127.7, 128.1, 128.5, 129.4, 130.9, 135.0, 138.1, 138.2, 139.5, 141.1, 144.3, 147.1, 156.8.

GC-MS: $m/z = 429 [M + 1]^+$.

Anal. Calcd for $C_{31}H_{28}N_2$: C, 86.88; H, 6.59; N, 6.54. Found: C, 86.82; H, 6.69; N, 5.97.

Paper

н

3'-Benzyl-5'-(4-phenylpiperazin-1-yl)[1,1':2',1"-terphenyl]-4'-carbonitrile (11b)

White solid; yield: 414 mg (0.82 mmol, 82%); mp 167–169 °C; R_f = 0.5 (EtOAc–hexane 1:49).

IR (ATR): 2215 cm⁻¹ (C≡N).

¹H NMR (400 MHz, CDCl₃): δ = 3.30–3.38 (m, 8 H, 4 × NCH₂), 4.08 (s, 2 H, CH₂), 6.72–6.84 (m, 5 H, ArH), 6.88–6.96 (m, 5 H, ArH), 6.99–7.07 (m, 9 H, ArH), 7.20 (t, *J* = 7.6 Hz, 2 H, ArH).

 ^{13}C NMR (100 MHz, CDCl₃): δ = 38.5, 49.6, 52.0, 107.3, 116.5, 117.9, 118.9, 120.1, 126.1, 126.9, 127.1, 127.7, 127.8, 128.2, 128.5, 129.2, 129.4, 130.8, 135.9, 137.9, 139.3, 140.8, 144.7, 147.4, 151.2, 155.3.

GC-MS: $m/z = 506 [M + 1]^+$.

Anal. Calcd for $C_{36}H_{31}N_3$: C, 85.51; H, 6.18; N, 8.31. Found: C, 85.02; H, 6.24; N, 8.13.

3'-Benzyl-4-chloro-5'-(piperidin-1-yl)[1,1':2',1"-terphenyl]-4'-carbonitrile (11c)

White solid; yield: 365 mg (0.79 mmol, 79%); mp 158–160 °C; R_f = 0.5 (EtOAc–hexane 1:49).

IR (ATR): 2215 cm⁻¹ (C≡N).

¹H NMR (400 MHz, CDCl₃): δ = 1.49–1.57 (m, 2 H, CH₂), 1.67–1.78 (m, 4 H, 2 × CH₂), 3.12 (t, *J* = 5.2 Hz, 4 H, 2 × NCH₂), 4.04 (s, 2 H, CH₂), 6.70–6.78 (m, 4 H, ArH), 6.81 (s, 1 H, ArH), 6.85 (d, *J* = 8.4 Hz, 2 H, ArH), 6.97–7.10 (m, 8 H, ArH).

 ^{13}C NMR (100 MHz, CDCl₃): δ = 24.1, 26.2, 38.4, 53.5, 107.4, 118.0, 118.7, 126.0, 127.0, 127.9, 128.1, 128.5, 128.7, 129.5, 130.7, 130.8, 134.9, 137.9, 139.3, 139.5, 144.6, 145.8, 156.8.

GC-MS: $m/z = 464 [M + 1]^+$, $465 [M + 2]^+$.

Anal. Calcd for $C_{31}H_{27}CIN_2$: C, 80.42; H, 5.88; N, 6.05. Found: C, 80.59; H, 5.96; N, 5.48.

3'-Benzyl-4-bromo-5'-(piperidin-1-yl)[1,1':2',1"-terphenyl]-4'-carbonitrile (11d)

White solid; yield: 415 mg (0.82 mmol, 82%); mp 150–152 °C; R_f = 0.5 (EtOAc–hexane 1:49).

IR (ATR): 2217 cm⁻¹ (C≡N).

¹H NMR (400 MHz, CDCl₃): δ = 1.49–1.57 (m, 2 H, CH₂), 1.68–1.77 (m, 4 H, 2 × CH₂), 3.12 (t, *J* = 5.2 Hz, 4 H, 2 × NCH₂), 4.04 (s, 2 H, CH₂), 6.69–6.79 (m, 6 H, ArH), 6.80 (s, 1 H, ArH), 6.97–7.08 (m, 6 H, ArH), 7.16 (d, *J* = 8.4 Hz, 2 H, ArH).

 ^{13}C NMR (100 MHz, CDCl₃): δ = 24.1, 26.2, 38.4, 53.5, 107.5, 118.0, 118.7, 121.3, 126.0, 127.0, 127.9, 128.1, 128.5, 130.8, 131.0, 134.8, 137.9, 138.0, 139.3, 140.0, 144.6, 145.7, 156.8.

GC-MS: $m/z = 508 [M + 1]^+$, 509 $[M + 2]^+$.

Anal. Calcd for $C_{31}H_{27}BrN_2$: C, 73.37; H, 5.36; N, 5.52. Found: C, 73.53; H, 5.44; N, 5.35.

3'-Benzyl-4-bromo-5'-(4-phenylpiperazin-1-yl)[1,1':2',1"-terphenyl]-4'-carbonitrile (11e)

White solid; yield: 467 mg (0.80 mmol, 80%); mp 170–172 °C; R_f = 0.5 (EtOAc–hexane 1:49).

IR (ATR): 2212 cm⁻¹ (C≡N).

¹H NMR (400 MHz, CDCl₃): δ = 3.31–3.37 (m, 8 H, 4 × NCH₂), 4.06 (s, 2 H, CH₂), 6.70–6.83 (m, 7 H, ArH), 6.86 (s, 1 H, ArH), 6.89 (d, *J* = 8.0 Hz, 2 H, ArH), 6.99–7.09 (m, 6 H, ArH), 7.12–7.23 (m, 4 H, ArH).

¹³C NMR (100 MHz, CDCl₃): δ = 38.5, 49.6, 51.9, 107.6, 116.5, 117.8, 118.7, 120.2, 121.5, 126.1, 127.2, 128.0, 128.2, 128.5, 129.2, 130.7, 130.9, 131.0, 135.8, 137.7, 139.2, 139.7, 145.0, 146.0, 151.2, 155.4. GC-MS: *m*/*z* = 585 [M + 1]⁺, 586 [M + 2]⁺.

Anal. Calcd for $C_{36}H_{30}BrN_3$: C, 73.97; H, 5.17; N, 7.19. Found: C, 74.01; H, 5.36; N, 6.99.

3'-Benzyl-4-methyl-5'-(piperidin-1-yl)[1,1':2',1"-terphenyl]-4'carbonitrile (11f)

White solid; yield: 419 mg (0.95 mmol, 95%); mp 156–158 °C; R_f = 0.5 (EtOAc–hexane 1:49).

IR (ATR): 2210 cm⁻¹ (C≡N).

¹H NMR (400 MHz, CDCl₃): δ = 1.47–1.57 (m, 2 H, CH₂), 1.68–1.77 (m, 4 H, 2 × CH₂), 2.15 (s, 3 H, CH₃), 3.12 (t, *J* = 5.2 Hz, 4 H, 2 × NCH₂), 4.04 (s, 2 H, CH₂), 6.76 (t, *J* = 8.4 Hz, 4 H, ArH), 6.80–6.87 (m, 5 H, ArH), 6.97–7.10 (m, 6 H, ArH).

 ^{13}C NMR (100 MHz, CDCl_3): δ = 21.1, 24.1, 26.2, 38.4, 53.6, 106.9, 118.2, 119.0, 125.9, 126.7, 127.7, 128.1, 128.4, 128.5, 129.3, 130.9, 135.0, 136.6, 138.1, 138.4, 139.5, 144.3, 147.1, 156.8.

GC-MS: $m/z = 443 [M + 1]^+$.

Anal. Calcd for $C_{32}H_{30}N_2$: C, 86.84; H, 6.83; N, 6.33. Found: C, 86.77; H, 6.82; N, 6.24.

3'-Benzyl-4-methoxy-5'-(piperidin-1-yl)[1,1':2',1"-terphenyl]-4'carbonitrile (11g)

White solid; yield: 421 mg (0.92 mmol, 92%); mp 95–97 °C; R_f = 0.5 (EtOAc–hexane 1:49).

IR (ATR): 2212 cm⁻¹ (C≡N).

¹H NMR (400 MHz, CDCl₃): δ = 1.48–1.59 (m, 2 H, CH₂), 1.68–1.77 (m, 4 H, 2 × CH₂), 3.12 (t, *J* = 5.2 Hz, 4 H, 2 × NCH₂), 3.63 (s, 3 H, OCH₃), 4.04 (s, 2 H, CH₂), 6.57 (d, *J* = 8.4 Hz, 2 H, ArH), 6.76 (t, *J* = 8.4 Hz, 4 H, ArH), 6.82–6.88 (m, 3 H, ArH), 6.98–7.10 (m, 6 H, ArH).

 ^{13}C NMR (100 MHz, CDCl_3): δ = 24.2, 26.2, 38.5, 53.6, 55.1, 106.8, 113.1, 118.3, 119.0, 125.9, 126.8, 127.8, 128.1, 128.5, 130.6, 130.9, 133.4, 135.0, 138.4, 139.5, 144.3, 146.7, 156.8, 158.5.

GC-MS: $m/z = 459 [M + 1]^+$.

Anal. Calcd for $C_{32}H_{30}N_2O$: C, 83.81; H, 6.59; N, 6.11. Found: C, 83.08; H, 6.70; N, 6.07.

3'-Benzyl-4-methoxy-5'-(4-phenylpiperazin-1-yl)[1,1':2',1"-terphenyl]-4'-carbonitrile (11h)

White solid; yield: 497 mg (0.93 mmol, 93%); mp 120–122 °C; R_f = 0.5 (EtOAc–hexane 1:49).

IR (ATR): 2209 cm⁻¹ (C≡N).

¹H NMR (400 MHz, CDCl₃): δ = 3.32–3.38 (m, 8 H, 4 × NCH₂), 3.64 (s, 3 H, OCH₃), 4.07 (s, 2 H, CH₂), 6.58 (d, J = 8.8 Hz, 2 H, ArH), 6.77 (t, J = 7.6 Hz, 4 H, ArH), 6.80–6.94 (m, 6 H, ArH), 6.98–7.11 (m, 6 H, ArH), 7.21 (t, J = 8.8 Hz, 2 H, ArH).

 ^{13}C NMR (100 MHz, CDCl₃): δ = 38.5, 49.6, 52.0, 55.2, 106.9, 113.2, 116.5, 118.1, 118.9, 120.2, 126.0, 126.9, 127.9, 128.1, 128.5, 129.2, 130.6, 130.8, 133.2, 135.9, 138.2, 139.4, 144.7, 147.0, 151.2, 155.3, 158.6.

GC-MS: $m/z = 536 [M + 1]^+$.

Anal. Calcd for $C_{37}H_{33}N_3O$: C, 82.96; H, 6.21; N, 7.84. Found: C, 82.86; H, 6.25; N, 7.73.

L

F. V. Singh, P. B. Kole

2-Benzyl-6-(naphthalen-2-yl)-4-(piperidin-1-yl)[1,1'-biphenyl]-3carbonitrile (11i)

White solid; yield: 430 mg (0.90 mmol, 90%); mp 182–184 °C; R_f = 0.5 (EtOAc–hexane 1:49).

IR (ATR): 2214 cm⁻¹ (C≡N).

¹H NMR (400 MHz, CDCl₃): δ = 1.63–1.71 (m, 2 H, CH₂), 1.82–1.90 (m, 4 H, 2 × CH₂), 3.28 (t, *J* = 5.2 Hz, 4 H, 2 × NCH₂), 4.22 (s, 2 H, CH₂), 6.90–6.96 (m, 4 H, ArH), 7.08–7.13 (m, 5 H, ArH), 7.14–7.23 (m, 3 H, ArH), 7.42–7.50 (m, 2 H, ArH), 7.56 (d, *J* = 8.4 Hz, 1 H, ArH), 7.64 (s, 1 H, ArH), 7.71–7.78 (m, 2 H, ArH).

 ^{13}C NMR (100 MHz, CDCl₃): δ = 24.2, 26.2, 38.4, 53.6, 107.3, 118.2, 119.3, 125.9, 126.1, 126.2, 126.8, 126.9, 127.4, 127.6, 127.8, 127.9, 128.1, 128.4, 128.5, 130.9, 132.1, 132.9, 135.1, 138.2, 138.8, 139.5, 144.5, 147.0, 156.9.

GC-MS: $m/z = 479 [M + 1]^+$.

Anal. Calcd for $C_{35}H_{30}N_2$: C, 87.83; H, 6.32; N, 5.85. Found: C, 83.69; H, 6.36; N, 5.58.

3'-Benzyl-6'-methyl-5'-(4-phenylpiperazin-1-yl)[1,1':2',1"-terphenyl]-4'-carbonitrile (11j)

White solid; yield: 384 mg (0.74 mmol, 74%); mp 178–180 °C; R_f = 0.5 (EtOAc–hexane 1:49).

IR (ATR): 2217 cm⁻¹ (C≡N).

¹H NMR (400 MHz, CDCl₃): δ = 1.99 (s, 3 H, CH₃), 3.22–3.60 (m, 8 H, 4 × NCH₂), 3.98 (s, 2 H, CH₂), 6.64 (dd, J_1 = 7.2 Hz, J_2 = 1.6 Hz, 2 H, ArH), 6.78 (dt, J_1 = 7.2 Hz, J_2 = 1.6 Hz, 5 H, ArH), 6.89–6.96 (m, 5 H, ArH), 6.95–7.09 (m, 6 H, ArH), 7.20 (t, J = 8.4 Hz, 2 H, ArH).

¹³C NMR (100 MHz, CDCl₃): δ = 17.2, 38.2, 50.5, 50.7, 111.4, 116.6, 118.5, 120.0, 126.0, 126.6, 127.4, 127.7, 128.1, 128.5, 129.1, 129.3, 130.3, 133.9, 138.6, 139.5, 139.6, 139.9, 141.4, 148.2, 151.8, 152.8.

GC-MS: $m/z = 520 [M + 1]^+$.

Anal. Calcd for $C_{37}H_{33}N_3$: C, 85.51; H, 6.40; N, 8.09. Found: C, 85.38; H, 6.70; N, 8.07.

3'-Benzyl-6'-methyl-5'-(piperidin-1-yl)[1,1':2',1"-terphenyl]-4'carbonitrile (111)

White solid; yield: 349 mg (0.79 mmol, 79%); mp 156–158 °C; R_f = 0.5 (EtOAc–hexane 1:49).

IR (ATR): 2213 cm⁻¹ (C≡N).

¹H NMR (400 MHz, CDCl₃): δ = 1.55–1.74 (m, 6 H, 3 × CH₂), 1.94 (s, 3 H, CH₃), 3.10–3.36 (m, 4 H, 2 × NCH₂), 3.96 (s, 2 H, CH₂), 6.63 (dd, *J*₁ = 7.6 Hz, *J*₂ = 2.0 Hz, 2 H, ArH), 6.74–6.80 (m, 4 H, ArH), 6.86–6.93 (m, 3 H, ArH), 6.94–7.10 (m, 6 H, ArH).

 ^{13}C NMR (100 MHz, CDCl_3): δ = 16.9, 24.3, 26.9, 38.1, 52.0, 110.5, 118.8, 125.9, 126.4, 126.5, 127.3, 127.6, 128.0, 128.5, 129.4, 130.3, 133.8, 138.7, 138.8, 139.7, 140.2, 141.0, 148.0, 154.5.

GC-MS: $m/z = 443 [M + 1]^+$.

Anal. Calcd for $C_{32}H_{30}N_2$: C, 86.84; H, 6.83; N, 6.33. Found: C, 86.62; H, 6.87; N, 6.11.

3'-Benzyl-5'-(methylthio)[1,1':2',1"-terphenyl]-4'-carbonitrile (12a)

A mixture of 4-(methylthio)-2-oxo-6-phenyl-2*H*-pyran-3-carbonitrile (**5a**; 243 mg, 1.0 mmol, 1.0 equiv), 1,3-diphenylacetone (**10**; 0.24 mL, 1.2 mmol, 1.2 equiv), and powdered KOH (84 mg, 1.5 mmol, 1.5 equiv) in DMF (5 mL) was stirred at r.t. for 12 h. The course of the reaction was monitored by TLC. On completion of the reaction, few ice pieces were added to the reaction mixture and neutralized with aq 2 M HCl. After that the reaction mixture was extracted with EtOAc (3 × 10 mL). The combined organic layers were dried (anhyd Na₂SO₄), filtered, and, concentrated under vacuum. The crude product was purified by neutral alumina column chromatography using EtOAc–hexane (1:49) as an eluent to afford **12a**; white solid; yield: 242 mg (0.62 mmol, 62%); mp 144–146 °C; $R_f = 0.4$ (EtOAc–hexane 1:49).

IR (ATR): 2211 cm⁻¹ (C≡N).

¹H NMR (400 MHz, CDCl₃): δ = 2.49 (s, 3 H, SCH₃), 4.07 (s, 2 H, CH₂), 6.72–6.77 (m, 4 H, ArH), 6.90–6.96 (m, 2 H, ArH), 6.98–7.09 (m, 9 H, ArH), 7.12 (s, 1 H, ArH).

 ^{13}C NMR (100 MHz, CDCl₃): δ = 14.7, 37.3, 110.7, 115.6, 124.4, 125.1, 126.1, 126.2, 126.7, 126.8, 127.1, 127.4, 128.3, 129.5, 136.5, 137.7, 137.8, 139.3, 142.2, 143.1, 145.6.

GC-MS: *m*/*z* = 392 [M + 1]⁺, 393 [M + 2]⁺.

Anal. Calcd for $C_{27}H_{21}NS$: C, 82.83; H, 5.41; N, 3.58; S, 8.19. Found: C, 82.21; H, 5.52; N, 3.42; S, 8.09.

Acknowledgment

Fateh V. Singh is thankful to the SAIF, VIT University, Vellore Campus for providing spectroscopic analysis. Priyanka B. Kole is grateful to VIT Chennai Campus for providing a fellowship.

Supporting Information

Supporting information for this article is available online at https://doi.org/10.1055/s-0037-1610332.

References

- (a) Canel, C.; Moraes, R. M.; Dayan, F. E.; Ferreira, D. *Photochemistry* **2000**, *54*, 115.
 (b) Tsutsui, C.; Yamada, Y.; Ando, M.; Toyama, D.; Wu, J.-l.; Wang, L.; Taketani, S.; Kataoka, T. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 4084.
- (2) (a) Mondal, S.; Panda, G. *RSC Adv.* **2014**, *4*, 28317. (b) Wood, P. M.; Woo, L. W. L.; Labrosse, J.-R.; Trusselle, M. N.; Abbate, S.; Longhi, G.; Castiglioni, E.; Lebon, F.; Purohit, A.; Reed, M. J.; Potter, B. V. L. *J. Med. Chem.* **2008**, *51*, 4226.
- (3) Yoshihara, H. A. I.; Apriletti, J. W.; Baxter, J. D.; Scanlan, T. S. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 2821.
- (4) Kong, X.; Chen, L.; Jiao, L.; Lian, F.; Lu, J.; Zhu, K.; Du, D.; Liu, J.; Ding, H.; Zhang, N.; Shen, J.; Zheng, M.; Chen, K.; Liu, X.; Jiang, H.; Luo, C. *J. Med. Chem.* **2014**, *57*, 9512; and the references cited therein.
- (5) (a) Wai, J. S.; Egbertson, M. S.; Payne, L. S.; Fisher, T. E.; Embrey, M. W.; Tran, L. O.; Melamed, M. W.; Langford, H. M.; Guare, J. P.; Zhuang, L.; Grey, V. E.; Vacca, J. P.; Holloway, M. K.; Naylor-Olsen, A. M.; Hazuda, D. J.; Felock, P. J.; Wolfe, A. L.; Stillmock, K. A.; Schleif, W. A.; Gabryelski, L. J.; Young, S. D. J. Med. Chem. 2000, 43, 4924. (b) Zhuang, L.; Wai, J. S.; Embrey, M. W.; Fisher, T. E.; Egbertson, M. S.; Payne, L. S.; Guare, J. P.; Vacca, J. P.; Hazuda, D. J.; Felock, P. J.; Wolfe, A. L.; Moyer, G.; Schlelf, W. A.; Gabryelski, L. J.; Leonard, Y. M.; Lynch, J. J.; Michelson, S. R.; Young, S. D. J. Med. Chem. 2003, 46, 453. (c) Long, Y.-Q.; Jiang, X.-H.; Dayam, R.; Sanchez, T.; Shoemaker, R.; Sel, S.; Neamati, N. J. Med. Chem. 2004, 47, 2561. (d) Cheltsov, A. V.; Aoyagi, M.;

Downloaded by: University at Buffalo (SUNY). Copyrighted material.

Paper

Aleshin, A.; Yu, C.-W. E.; Gilliland, T.; Zhai, D.; Bobkov, A. A.; Reed, J. C.; Liddington, R. C.; Abagyan, R. *J. Med. Chem.* **2010**, *53*, 3899.

- (6) (a) Procopiou, P. A.; Browning, C.; Buckley, J. M.; Clark, K. L.; Fechner, L.; Gore, P. M.; Hancock, A. P.; Hodgson, S. T.; Holmes, D. S.; Kranz, M.; Looker, B. E.; Morriss, K. M. L.; Parton, D. L.; Russell, L. J.; Slack, R. J.; Sollis, S. L.; Vile, S.; Watts, C. J. *J. Med. Chem.* 2011, 54, 2183. (b) Procopiou, P. A.; Ford, A. J.; Gore, P. M.; Looker, B. E.; Hodgson, S. T.; Holmes, D. S.; Vile, S.; Clark, K. L.; Saunders, K. A.; Slack, R. J.; Rowedder, J. E.; Watts, C. J. ACS *Med. Chem. Lett.* 2017, 8, 577.
- (7) (a) Ohtake, Y.; Sato, T.; Kobayashi, T.; Nishimoto, M.; Taka, N.; Takano, K.; Yamamoto, K.; Ohmori, M.; Yamaguchi, M.; Takami, K.; Yeu, S.-Y.; Ahn, K.-H.; Matsuoka, H.; Morikawa, K.; Suzuki, M.; Hagita, H.; Ozawa, K.; Yamaguchi, K.; Kato, M.; Ikeda, S. *J. Med. Chem.* **2012**, *55*, 7828. (b) Li, Y.; Shi, Z.; Chen, L.; Zheng, S.; Li, S.; Xu, B.; Liu, Z.; Liu, J.; Deng, C.; Ye, F. *J. Med. Chem.* **2017**, 60. 4173.
- (8) Mahesh, S.; Anand, R. V. Org. Biomol. Chem. 2017, 15, 8393.
- (9) (a) Novelli, A.; Rosi, E. J. Chemother. 2017, 29, 10. (b) Wang, S.;
 Yin, Y.; Wang, J. Appl. Microbiol. Biotechnol. 2018, 102, 1997.
- (10) (a) Takamatsu, S.; Hodges, T. W.; Rajbhandari, I.; Gerwick, W. H.; Hamann, M. T.; Nagle, D. G. *J. Nat. Prod.* **2003**, *66*, 605.
 (b) Wegener, A.; Miller, K. A. J. Org. Chem. **2017**, *82*, 11655; and references cited therein.
- (11) (a) Jablonicka, V.; Ziegler, J.; Vatehova, Z.; Liskova, D.; Heilmann,
 I.; Oblozinsky, M.; Heilmann, M. J. Plant Physiol. 2018, 223, 1.
 (b) Yang, X.; Tsui, G. C. Org. Lett. 2018, 20, 1179.
- (12) Kern, L.; Xu, R.; Julien, S.; Suter, D. M.; Preynat-Seauve, O.; Baquie, M.; Poncet, A.; Combescure, C.; Stoppini, L.; Thriel, C. V.; Krause, K.-H. *Curr. Med. Chem.* **2013**, *20*, 710.
- (13) Kito, Y.; Suzuki, H.; Edwards, F. R. J. Smooth Muscle Res. 2002, 38, 165.
- (14) Xu, M.-M.; Wang, H.-Q.; Wan, Y.; He, G.; Yan, J.; Zhang, S.; Wang, S.-L.; Shi, F. Org. Chem. Front. **2017**, *4*, 358.
- (15) Liang, F.; Ji, X.; Zhang, J.; Cao, S. Org. Chem. Front. 2016, 3, 1425.
- (16) (a) Chowdhury, S.; Georghiou, P. E. *Tetrahedron Lett.* **1999**, *40*, 7599. (b) Nobre, S. M.; Monteiro, A. L. *Tetrahedron Lett.* **2004**, *45*, 8225. (c) Liegault, B.; Renaud, J.-L.; Bruneau, C. *Chem. Soc. Rev.* **2008**, *37*, 290. (d) Zhao, G.; Zhang, K.; Wang, L.; Li, J.; Zou, D.; Wu, Y.; Wu, Y. *Tetrahedron Lett.* **2015**, *56*, 6700.
- (17) Xu, W.; Paira, R.; Yoshikai, N. Org. Lett. 2015, 17, 4192.
- (18) Zhang, J.; Lu, G.; Sun, H.; Shen, Q. Org. Lett. 2016, 18, 2860.
- (19) Mahesh, S.; Kant, G.; Anand, R. V. RSC Adv. 2016, 6, 80718.

Downloaded by: University at Buffalo (SUNY). Copyrighted material.

- (20) Hemelaere, R.; Champagne, P. A.; Desroches, J.; Paquin, J.-F. J. Fluorine Chem. 2016, 190, 1.
- (21) Ueda, M.; Nakakoji, D.; Kuwahara, Y.; Nishimura, K.; Ryu, I. *Tet-rahedron Lett.* **2016**, *57*, 4142.
- (22) (a) Goal, A.; Singh, F. V.; Dixit, M.; Verma, D.; Raghunandan, R.; Maulik, P. R. Chem. Asian. J. 2007, 2, 239. (b) Singh, F. V.; Chaurasia, S.; Joshi, M. D.; Srivastava, A. K.; Goel, A. Bioorg. Med. Chem. Lett. 2007, 17, 2425. (c) Goal, A.; Ram, V. J. Tetrahedron 2009, 65, 7865.
- (23) (a) Singh, F. V.; Kumar, V.; Goal, A. Synlett 2007, 13, 2086.
 (b) Singh, F. V.; Kumar, V.; Kumar, B.; Goal, A. Tetrahedron 2007, 63, 10971. (c) Goal, A.; Singh, F. V.; Kumar, V.; Reichert, M.; Gulder, T. A. M.; Bringmann, G. J. Org. Chem. 2007, 72, 7765.
 (d) Kumar, A.; Singh, F. V.; Goal, A. Tetrahedron Lett. 2007, 48, 8223. (e) Goel, A.; Kumar, V.; Hemberger, Y.; Singh, F. V.; Nag, P.; Knauer, M.; Kant, R.; Raghunandan, R.; Maulik, P. R.; Bringmann, G. J. Org. Chem. 2016, 81, 10721.
- (24) (a) Goal, A.; Singh, F. V.; Sharon, A.; Maulik, P. R. Synlett 2005, 623. (b) Goal, A.; Singh, F. V.; Verma, D. Synlett 2005, 2027. (c) Goel, A.; Taneja, G.; Raghuvanshi, A.; Kant, R.; Maulik, P. R. Org. Biomol. Chem. 2013, 11, 5239.
- (25) (a) Goel, A.; Singh, S. P.; Kumar, A.; Kant, R.; Maulik, P. R. Org. Lett. 2009, 11, 5122. (b) Goel, A.; Kumar, V.; Chaurasia, S.; Rawat, M.; Prasad, R.; Anand, R. S. J. Org. Chem. 2010, 75, 3656. (c) Maurya, H. K.; Tandon, V. K.; Kumar, B.; Kumar, A.; Huch, V.; Ram, V. J. Org. Biomol. Chem. 2012, 10, 605. (d) Goel, A.; Kumar, V.; Singh, S. P.; Sharma, A.; Prakash, S.; Singh, C.; Anand, R. S. J. Mater. Chem. 2012, 22, 14880. (e) Goel, A.; Sharma, A.; Kathuria, M.; Bhattacharjee, A.; Verma, A.; Mishra, P. R.; Nazir, A.; Mitra, K. Org. Lett. 2014, 16, 756. (f) Goel, A.; Umar, S.; Nag, P.; Sharma, A.; Kumar, L.; Shamsuzzama Hossain, Z.; Gayen, J. R.; Nazir, A. Chem. Commun. 2015, 51, 5001. (g) Sharma, A.; Umar, S.; Kar, P.; Singh, K.; Sachdev, M.; Goel, A. Analyst 2016, 141, 137. (h) Taneja, G.; Gupta, C. P.; Mishra, S.; Srivastava, R.; Rahuja, N.; Rawat, A. K.; Pandey, J.; Gupta, A. P.; Jaiswal, N.; Jiaur, G. R.; Tamrakar, A. K.; Srivastava, A. K.; Goel, A. Med. Chem. Commun. 2017, 8, 329.
- (26) Shetgaonkar, S. E.; Singh, F. V. Synthesis 2018, 50, 3540.
- (27) (a) Goel, A.; Singh, F. V. Tetrahedron Lett. 2005, 46, 5585.
 (b) Goel, A.; Verma, D.; Singh, F. V. Tetrahedron Lett. 2005, 46, 8487.
 (c) Singh, F. V.; Kumar, A.; Goel, A. Tetrahedron Lett. 2006, 47, 7767.
 (d) Kumar, V.; Singh, F. V.; Parihar, A.; Goel, A. Tetrahedron Lett. 2009, 50, 680.
 (e) Goel, A.; Kumar, V.; Nag, P.; Bajpai, V.; Kumar, B.; Singh, C.; Prakash, S.; Anand, R. S. J. Org. Chem. 2011, 76, 7474.